New sight saving treatments now available on the NHS
Patients living with potentially blinding condition uveitis are now able to benefit from two new sight saving treatments.
Uveitis is an inflammatory condition that causes damage to the eye resulting in loss of vision. RNIB worked with uveitis patients to call on the National Institute of Health and Care Excellence (NICE) to make dexamethasone (Ozurdex) and adalimumab (Humira) available on the NHS in England. NICE has now published guidance making the treatments available to adult patients in England.
The two drugs are being used to treat patients with uveitis in the back of the eye, or posterior. This is great news, particularly for uveitis patients most at risk of blindness. This group of patients have exhausted all the current treatment options and were facing the possibility of losing their sight permanently, they now have another option.
RNIB is hugely grateful to the patients that shared their experiences of living with uveitis. Your voices helped us make our case to NICE and achieve this treatment success!